Cargando…
Quantitative Analysis of Anti-N and Anti-S Antibody Titers of SARS-CoV-2 Infection after the Third Dose of COVID-19 Vaccination
We quantitatively analyzed SARS-CoV-2 antibody levels in patients after two doses of the ChAdOx1 nCoV-19 vaccine and the third BNT162b2 booster. We obtained 255 serum samples from 149 healthcare workers 1 and 4 months after the third dose. Of the 149 participants, 58 (38.9%) experienced COVID-19 inf...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321317/ https://www.ncbi.nlm.nih.gov/pubmed/35891307 http://dx.doi.org/10.3390/vaccines10071143 |
_version_ | 1784756015348056064 |
---|---|
author | Lee, Nuri Jeong, Seri Lee, Su Kyung Cho, Eun-Jung Hyun, Jungwon Park, Min-Jeong Song, Wonkeun Kim, Hyun Soo |
author_facet | Lee, Nuri Jeong, Seri Lee, Su Kyung Cho, Eun-Jung Hyun, Jungwon Park, Min-Jeong Song, Wonkeun Kim, Hyun Soo |
author_sort | Lee, Nuri |
collection | PubMed |
description | We quantitatively analyzed SARS-CoV-2 antibody levels in patients after two doses of the ChAdOx1 nCoV-19 vaccine and the third BNT162b2 booster. We obtained 255 serum samples from 149 healthcare workers 1 and 4 months after the third dose. Of the 149 participants, 58 (38.9%) experienced COVID-19 infection during the 4-month study period, with infection occurring 7–62 days before the second blood draw. Total antibody titers against the anti-spike (anti-S) and anti-nucleocapsid (anti-N) proteins of SARS-CoV-2 were measured using Elecsys Anti-SARS-CoV-2 S and Elecsys Anti-SARS-CoV-2 assays (Roche), respectively. The median anti-S antibody titer in the non-infected groups at 4 months after the third dose was significantly decreased compared to that at 1 month after the third dose (from 17,777 to 3673 U/mL, p < 0.001). The infected group showed higher median anti-S antibody titers at 4 months (19,539 U/mL) than the non-infected group (3673 U/mL). The median anti-N antibody titer in the infected group at 4 months after the third dose was a 5.07 cut-off index (79.3% positivity). Anti-N antibody titers in the infected group were correlated with the number of days after SARS-CoV-2 infection. These data provide useful information for determining quarantine strategies and fourth vaccination requirements. |
format | Online Article Text |
id | pubmed-9321317 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93213172022-07-27 Quantitative Analysis of Anti-N and Anti-S Antibody Titers of SARS-CoV-2 Infection after the Third Dose of COVID-19 Vaccination Lee, Nuri Jeong, Seri Lee, Su Kyung Cho, Eun-Jung Hyun, Jungwon Park, Min-Jeong Song, Wonkeun Kim, Hyun Soo Vaccines (Basel) Article We quantitatively analyzed SARS-CoV-2 antibody levels in patients after two doses of the ChAdOx1 nCoV-19 vaccine and the third BNT162b2 booster. We obtained 255 serum samples from 149 healthcare workers 1 and 4 months after the third dose. Of the 149 participants, 58 (38.9%) experienced COVID-19 infection during the 4-month study period, with infection occurring 7–62 days before the second blood draw. Total antibody titers against the anti-spike (anti-S) and anti-nucleocapsid (anti-N) proteins of SARS-CoV-2 were measured using Elecsys Anti-SARS-CoV-2 S and Elecsys Anti-SARS-CoV-2 assays (Roche), respectively. The median anti-S antibody titer in the non-infected groups at 4 months after the third dose was significantly decreased compared to that at 1 month after the third dose (from 17,777 to 3673 U/mL, p < 0.001). The infected group showed higher median anti-S antibody titers at 4 months (19,539 U/mL) than the non-infected group (3673 U/mL). The median anti-N antibody titer in the infected group at 4 months after the third dose was a 5.07 cut-off index (79.3% positivity). Anti-N antibody titers in the infected group were correlated with the number of days after SARS-CoV-2 infection. These data provide useful information for determining quarantine strategies and fourth vaccination requirements. MDPI 2022-07-18 /pmc/articles/PMC9321317/ /pubmed/35891307 http://dx.doi.org/10.3390/vaccines10071143 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lee, Nuri Jeong, Seri Lee, Su Kyung Cho, Eun-Jung Hyun, Jungwon Park, Min-Jeong Song, Wonkeun Kim, Hyun Soo Quantitative Analysis of Anti-N and Anti-S Antibody Titers of SARS-CoV-2 Infection after the Third Dose of COVID-19 Vaccination |
title | Quantitative Analysis of Anti-N and Anti-S Antibody Titers of SARS-CoV-2 Infection after the Third Dose of COVID-19 Vaccination |
title_full | Quantitative Analysis of Anti-N and Anti-S Antibody Titers of SARS-CoV-2 Infection after the Third Dose of COVID-19 Vaccination |
title_fullStr | Quantitative Analysis of Anti-N and Anti-S Antibody Titers of SARS-CoV-2 Infection after the Third Dose of COVID-19 Vaccination |
title_full_unstemmed | Quantitative Analysis of Anti-N and Anti-S Antibody Titers of SARS-CoV-2 Infection after the Third Dose of COVID-19 Vaccination |
title_short | Quantitative Analysis of Anti-N and Anti-S Antibody Titers of SARS-CoV-2 Infection after the Third Dose of COVID-19 Vaccination |
title_sort | quantitative analysis of anti-n and anti-s antibody titers of sars-cov-2 infection after the third dose of covid-19 vaccination |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321317/ https://www.ncbi.nlm.nih.gov/pubmed/35891307 http://dx.doi.org/10.3390/vaccines10071143 |
work_keys_str_mv | AT leenuri quantitativeanalysisofantinandantisantibodytitersofsarscov2infectionafterthethirddoseofcovid19vaccination AT jeongseri quantitativeanalysisofantinandantisantibodytitersofsarscov2infectionafterthethirddoseofcovid19vaccination AT leesukyung quantitativeanalysisofantinandantisantibodytitersofsarscov2infectionafterthethirddoseofcovid19vaccination AT choeunjung quantitativeanalysisofantinandantisantibodytitersofsarscov2infectionafterthethirddoseofcovid19vaccination AT hyunjungwon quantitativeanalysisofantinandantisantibodytitersofsarscov2infectionafterthethirddoseofcovid19vaccination AT parkminjeong quantitativeanalysisofantinandantisantibodytitersofsarscov2infectionafterthethirddoseofcovid19vaccination AT songwonkeun quantitativeanalysisofantinandantisantibodytitersofsarscov2infectionafterthethirddoseofcovid19vaccination AT kimhyunsoo quantitativeanalysisofantinandantisantibodytitersofsarscov2infectionafterthethirddoseofcovid19vaccination |